BridgeBio Signals Breakout Growth with Attruby Boom, Trio of FDA Reviews

PALO ALTO, CA – August 10, 2026 – In a powerful demonstration of business momentum, BridgeBio Pharma has unveiled second-quarter results that signal its definitive arrival as a major commercial force in the biopharmaceutical landscape. Propelled by blockbuster-in-the-making sales of its heart disease drug Attruby, the company is not just resting on its laurels. Instead, it is leveraging that success to fuel an aggressive expansion, with three more potential therapies for rare genetic diseases now under review by the FDA. Bolstered by a fresh $1 billion in financing, BridgeBio is sending clear growth signals that it is transitioning from a promising pipeline company to a multi-product commercial powerhouse.

Attruby's Commercial Ascent and Market Disruption

The primary engine of BridgeBio's current success is Attruby (acoramidis), a treatment for the rare and fatal heart condition transthyretin amyloid cardiomyopathy (ATTR-CM). The company reported a staggering $222.4 million in U.S. net product revenue for Attruby in the second quarter, a more than 200% increase from the same period last year. This surge, which exceeded analyst expectations, is being driven by strong uptake in the treatment-naïve segment, where physicians are increasingly choosing Attruby as the first-line therapy for their patients.

“We continue to see strong growth this quarter for Attruby with our first-line share climbing again,” said Matt Outten, Chief Commercial Officer of BridgeBio. This momentum is a critical signal in a competitive market that includes established players. Real-world data is beginning to tell a story of clinical differentiation that resonates with prescribers. An independent, propensity-matched analysis published in JSCAI found that patients taking Attruby had a 37% lower risk of composite cardiovascular events and a 34% reduction in hospitalizations at six months compared to those on the market's incumbent therapy, tafamidis.

Further strengthening its clinical case, new post-hoc analyses published in Circulation: Heart Failure revealed that Attruby is the first ATTR-CM therapy to demonstrate direct kidney-protective effects, a profile similar to well-established kidney medicines. This is a significant development for ATTR-CM patients, for whom multi-organ health is a major concern. The combination of strong commercial execution and a compelling, expanding clinical profile suggests Attruby’s growth trajectory is not only steep but sustainable.

The Next Wave: A Pipeline on the Cusp of Delivery

While Attruby's performance is impressive, the most significant growth signal for BridgeBio is the rapid maturation of its late-stage pipeline. The company has successfully submitted New Drug Applications (NDAs) for three distinct therapies, effectively setting the stage for a cascade of potential launches over the next year.

First in line is BBP-418 for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), a debilitating genetic disease with no approved treatments. The FDA has granted the application Priority Review, setting a target action date of November 27, 2026. A potential approval would be a landmark moment, not just for BridgeBio, but for the entire LGMD community.

Following closely is encaleret for autosomal dominant hypocalcemia type 1 (ADH1), another condition lacking a specifically indicated therapy. It too has received Priority Review, with an FDA decision expected by May 8, 2027. BridgeBio is already seeing an acceleration in ADH1 diagnoses, with roughly 70 new patients identified each month under a dedicated diagnostic code, indicating a ready and waiting patient population.

Rounding out the trio is oral infigratinib for achondroplasia, the most common form of dwarfism. With Phase 3 results published in the prestigious New England Journal of Medicine—a notable seal of scientific validation—the company has submitted its NDA and anticipates a U.S. launch in mid-2027. This therapy has the potential to become a best-in-class oral option for children with the condition.

“This was the quarter all three of our pipeline programs... moved from data into active regulatory review, with our first PDUFA date now set for November 27, 2026, which is a level of strategic execution and discipline I'm proud of,” said Neil Kumar, Ph.D., Co-Founder and CEO of BridgeBio.

Fueling the Engine for Multi-Launch Execution

Executing on one commercial launch is a challenge; preparing for three simultaneously requires immense resources and strategic foresight. Here, BridgeBio has sent perhaps its strongest signal of confidence. The company ended the quarter with $720.2 million in cash, a figure that does not include a massive $1 billion preferred equity financing that closed on July 1. This infusion brings the company's pro forma cash position to approximately $1.7 billion.

This war chest is critical. It de-risks the upcoming launches, allowing the company to invest heavily in commercial readiness, market access, and patient education without diverting resources from its ongoing research and development engine. Operating expenses have indeed risen to $350.8 million for the quarter, reflecting these pre-commercial investments, but they are foundational for capturing the full value of these potential new medicines.

As Dr. Kumar noted, the financing provides a “balance sheet sized to run all three launches at full strength.” For investors and analysts decoding the company’s momentum, this strategic capitalization is a clear indicator that BridgeBio is not just planning for growth—it is actively building the infrastructure to support and sustain it across multiple fronts.